AstraZeneca’s Camizestrant Gets EU Approval for Advanced Breast Cancer
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has just delivered a landmark decision: eight new medicines recommended for approval in a single meeting, including two firsts that could reshape cancer treatment in Europe. Among them, AstraZeneca’s Etcamah (camizestrant) has secured a positive opinion for treating advanced breast cancer in patients … Read more